AzTrials
AzTrials

Healthy VolunteersNCT02167178

The Relationship Between Cardiac Output and Microvascular Visceral Blood Flow

An observational study of Healthy Volunteers, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Although major surgery is often required to treat abdominal problems, there is a significant risk of death or complication following these operations. By using ultrasound the amount and timing of fluid patients receive during operations can be optimised and the risk of surgery reduced. Read more about this study

Who is it for?
Ages 18 to 80 years, men onlyHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
Administration of 0.9% NaCl solution, Measurement of stroke volume and Measurement of microvascular blood flow
How many people
24 participants
Where
1 siteUnited Kingdom
Study dates
Jan 2013to Aug 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Healthy male volunteers, aged 18-80.

Who may be able to join

  • male
  • age 18-80 years
  • body mass index 20-30kg/m2

Who cannot join

  • BMI < 20 or > 30 kg/m2.
  • Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arhythmias , right to left cardiac shunt or recent cardiac event.
  • Individuals taking beta-adrenergic blocking agents.
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)..
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes.
  • Active inflammatory bowel disease, or renal disease,
Show all 14Show fewer
  • Malignancy
  • Clotting dysfunction
  • Previous oesophageal surgery
  • Individuals with a known history of oesophageal varices
  • Individuals with a known history of epistaxis
  • Family history of early (<55y) death from cardiovascular disease.
  • Known sensitivity to SonoVue
  • Known sensitivity to gelofusine

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • University of Nottingham, School of Medicine, Division of Medical Sciences and Graduate Entry Medicine

    Derby, Derbyshire, DE22 3DT

Other trials in United Kingdom

About this study

Official title: Investigation of the Relationship Between Oesophageal Doppler Assessed Increases in Cardiac Output and Microvascular Visceral Blood Flow in Healthy Volunteers

Although major surgery is often required to treat abdominal problems, there is a significant risk of death or complication following these operations. By using ultrasound the amount and timing of fluid patients receive during operations can be optimised and the risk of surgery reduced. However, little is known about the exact changes in blood flow in the small vessels of the body in response to fluid. A greater understanding of this may allow for more appropriate care of patients undergoing this type of surgery in the future.

In this study of healthy volunteers we will attempt to better understand how fluid administration guided by ultrasound effects blood flow in large and small vessels, by using two different techniques of ultrasound imaging. A narrow bore (approximately 4-5mm diameter) ultrasound probe will be passed through the nostril and mouth to rest within the oesophagus allowing measurement of blood flow in the main artery, while a second probe will be rested on the volunteer's abdomen and used to record changes in blood flow in small liver blood vessels. Comparison of these two techniques during the administration of fluid will allow us to better understand the relationship between large and small vessel blood flow.

Because different types of fluid may behave in different ways, we will test the effect of two types of fluid commonly used in clinical practice; 'normal' saline solution and gelofusine.

Read the detailed description

Optimizing intravascular volume and cardiac output are essential to ensure adequate organ perfusion in patients who are undergoing major surgery. To enable this cardiac output is frequently monitored during operation using a variety of techniques; one such technique is trans-oesophageal Doppler ultrasound also known as oesophageal Doppler monitoring (ODM). ODM measurement of cardiac output is a less invasive technique than many currently used methods, and has recently been recommended by NICE for adoption in clinical practice.

The matching of microvascular blood flow, cardiac output and fluid administration is advantageous for visceral organs, in marrying demands for oxygen and nutrients to their delivery. However, although there is evidence to suggest that intraoperative ODM directed fluid administration can improve outcomes in the perioperative period, reducing hospital stay and complications, there is little direct evidence that optimization of cardiac output via ODM improves the microvascular blood flow to the visceral organs which are frequently compromised by major surgical interventions. A greater appreciation of the effect of ODM guided fluid replacement on the delivery of blood and hence oxygen and nutrients to these vital organs could help with the development of more refined algorithms for fluid administration in a clinical setting in the future. In our clinical physiology laboratories we regularly employ contrast-enhanced ultrasound (CEUS) using a Phillips iU22, to visualize microvascular blood flow in healthy young and elderly men following a variety of physiological challenges. This minimally invasive ultrasound based imaging technique is ideal for gaining an insight into the effect various physiological interventions have on tissue blood flow and could be readily used to chart changes in visceral microvascular flow following ODM guided fluid optimization. Transference of this investigative approach to a clinical setting has the potential to greatly improve the care of the surgical patient requiring fluid resuscitation.

Different types of intravenous fluids are used in clinical practice. These are primarily crystalloid solutions, such as 0.9% sodium chloride ('normal' saline), or colloidal suspensions, such as gelofusine. There is good experimental evidence that the colloid gelofusine produces a greater effect on cardiac output than an equivalent volume of of saline, but it is unclear if this effect is replicated in the microvasculature.

We will test the hypotheses: (1) cardiac output and stroke volume as measured by ODM are determinants of visceral microvascular blood flow (2) visceral microvascular blood flow in elderly individuals is more closely determined by stroke volume (3) gelofusine produces a greater increase in microvascular blood flow than the same volume of normal saline.

Being tested
Administration of 0.9% NaCl solution, Measurement of stroke volume, Measurement of microvascular blood flow, Administration of gelofusine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Administration of 0.9% NaCl solutionOther

    Also called Normal saline, Saline

    Volunteers administered 0.9% NaCl solution in 250ml boluses

  • Measurement of stroke volumeOther

    The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.

  • Measurement of microvascular blood flowOther

    Also called CEUS, Contrast enhanced ultrasound scan, SonoVue.

    Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.

  • Administration of gelofusineOther

    Volunteers administered gelofusine in 250ml boluses

Study groups in NCT02167178
Study groupRoleWhat they receive
Volunteers receiving 0.9% NaClVolunteers receiving 0.9% NaCl to optimise stroke volume
Receives: Other: Administration of 0.9% NaCl solution; Other: Measurement of stroke volume; Other: Measurement of microvascular blood flow
Volunteers receiving gelofusineVolunteers receiving gelofusine to optimise stroke volume
Receives: Other: Measurement of stroke volume; Other: Measurement of microvascular blood flow; Other: Administration of gelofusine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in microvascular visceral blood flow

    Microvascular visceral blood flow is assessed using contrast enhanced ultrasound scanning, following stroke volume optimisation.

    Measured: 30 minutes

Secondary outcomes (2)
  1. Change in stroke volume

    The change in stroke volume will be assessed using an Oesophageal Doppler Monitor, and will be assessed pre- and post-intravenous fluid administration.

    Measured: 30 minutes

  2. Change in haematocrit

    The change in the haematocrit will be measured pre- and post-intravenous fluid administration.

    Measured: 60 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2014 (estimated)
  2. Study startJan 2013
  3. Primary completionMar 2014
  4. Study completionAug 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02167178
Sponsor's protocol ID
A12012012
Status last verified
Jan 2015
First submitted
16 Jun 2014
Last updated
27 Jan 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Healthy Volunteers, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in microvascular visceral blood flow (time frame: 30 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in